Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 6/20 | 0.53 |
| ▸ | LAP3 | P28838 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777968 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL30676222 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL30453786 | 0.97 | ALDH1A1 (0.53) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL29449455 | 0.92 | MME (0.56) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL31031454 | 0.91 | MME (0.56) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL30454933 | 0.91 | ALDH1A1 (0.47) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL29531317 | 0.91 | ALDH1A1 (0.47) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL8945568 | 0.89 | PDCD1LG2 (0.53) | ALDH1A1MEN1LMNAKMT2AMME | |
| SCHEMBL30381706 | 0.89 | PDCD1LG2 (0.47) | ALDH1A1MEN1LMNAKMT2AMME | |
| Leu-Leu SCHEMBL6044006 | 0.89 | ALDH1A1 (0.60) | ALDH1A1MEN1LMNAKMT2AMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| US-20250263437-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| WO-2024132726-A1 | SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE | UNIWERSYTET GDANSKI (PL) | 2024-06-27 | — | — | WO | claimed |
| US-20240165006-A1 | DERMATOLOGICAL COMPOSTIONS AND USE THEREOF | BONE SCI. BIO LTD. (IL) | 2024-05-23 | — | — | US | claimed |
| CN-114813994-B | Serum metabolite marker for noninvasive diagnosis of epileptic seizure control patient and application thereof | 郑州大学第一附属医院 | 2024-02-09 | — | — | CN | claimed |
| EP-4313105-A1 | DERMATOLOGICAL COMPOSITIONS AND USE THEREOF | Bone Sci. Bio Ltd. (IL) | 2024-02-07 | — | — | EP | claimed |
| CN-117083075-A | Dermatological composition and use thereof | 邦赛生物有限公司 | 2023-11-17 | — | — | CN | claimed |
| EP-4276105-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd (CN) | 2023-11-15 | — | — | EP | claimed |
| CN-116041476-B | MALK derived from pig liver to express antibacterial peptide, and preparation method and application thereof | 东北农业大学 | 2023-10-27 | — | — | CN | claimed |
| CN-116041476-A | MALK derived from pig liver to express antibacterial peptide, and preparation method and application thereof | 东北农业大学 | 2023-05-02 | — | — | CN | claimed |
| US-20230130132-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMPHIPHILIC PEPTIDES AND METHODS OF USE THEREOF | BONE SCI. BIO LTD. (IL) | 2023-04-27 | — | — | US | claimed |
| EP-4125993-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMPHIPHILIC PEPTIDES AND METHODS OF USE THEREOF | Bone Sci. Bio Ltd. (IL) | 2023-02-08 | — | — | EP | claimed |
| EP-4090372-A1 | TARGETING PAR1 AND PAR2 TO REGULATE LIPID AND CHOLESTEROL ABUNDANCE | Mayo Foundation for Medical Education and Research (US) | 2022-11-23 | — | — | EP | claimed |
| WO-2022201146-A1 | DERMATOLOGICAL COMPOSITIONS AND USE THEREOF | BONE SCI. BIO LTD. (IL) | 2022-09-29 | — | — | WO | claimed |
| CN-114805489-A | Polypeptide for repairing skin injury or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022148289-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | 四川好医生攀西药业有限责任公司 | 2022-07-14 | — | — | WO | claimed |
| US-20220048988-A1 | CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME | CHILDREN'S NATIONAL MEDICAL CENTER | 2022-02-17 | — | — | US | claimed |
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | IPSEN BIOPHARM LIMITED (GB) | 2026-03-31 | — | — | US | disclosed |
| EP-4039710-B1 | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 | SANOFI SA (FR) | 2026-03-25 | — | — | EP | disclosed |
| US-12570755-B2 | Anti-CD20 antibody and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12537071-B1 | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins | BERMUDES DAVID GORDON (US) | 2026-01-27 | — | — | US | disclosed |
| US-12522664-B2 | Anti-CD20 antibody and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025222300-A1 | ATRIAL NATRIURETIC PEPTIDE CONSTRUCTS FOR TARGETED PAYLOAD DELIVERY TO NPR-C EXPRESSING CELLS | PROTEINQURE INC. (CA) | 2025-10-30 | — | — | WO | disclosed |
| US-20250333464-A1 | IL10 AGONISTS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250312475-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | SANOFI (FR) | 2025-10-09 | — | — | US | disclosed |
| US-20250263437-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250195626-A1 | TREATMENT OF PAIN & INFLAMMATORY DISORDERS | IPSEN BIOPHARM LTD (GB) | 2025-06-19 | — | — | US | disclosed |
| US-20250154549-A1 | GLYCOSYLTRANSFERASE VARIANT, AND METHOD OF PREPARING STEVIOL GLYCOSIDES USING SAME | SAMYANG CORPORATION (KR) | 2025-05-15 | — | — | US | disclosed |
| WO-2025085867-A1 | COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCERS | A2 BIOTHERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4536676-A2 | METHODS FOR PURIFICATION OF MULTI-SPECIFIC ANTIBODIES | Sanofi (FR) | 2025-04-16 | — | — | EP | disclosed |
| CN-119799830-A | Danfeng peony peptide with whitening, moisturizing, tightening and collagen synthesis promoting functions and preparation method and application thereof | 厦门元之道生物科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-112423779-B | Peptides for the treatment of retinitis pigmentosa | 第一三共株式会社 | 2025-04-11 | — | — | CN | disclosed |
| CN-119776332-A | Enzymatic preparation process of histamine dihydrochloride | 上海瀚鸿科技股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12259397-B2 | Biomarkers related to organ function | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250066755-A1 | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS | IPSEN BIOPHARM LTD (GB) | 2025-02-27 | — | — | US | disclosed |
| US-20250051818-A1 | PRODUCTION OF REBAUDIOSIDE | SAMYANG CORPORATION (KR) | 2025-02-13 | — | — | US | disclosed |
| US-20250025520-A1 | MICROBE-BASED MODULATION OF SEROTONIN BIOSYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-23 | — | — | US | disclosed |
| CN-119343359-A | Method for purifying multispecific antibodies | 赛诺菲 | 2025-01-21 | — | — | CN | disclosed |
| CN-119291194-A | Method for quantifying a polypeptide | 建新公司 | 2025-01-10 | — | — | CN | disclosed |
| US-12187772-B2 | IL10 agonists and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-110256569-B | Dual variable region antibody-like binding proteins with exchange binding region orientation | 赛诺菲 | 2025-01-07 | — | — | CN | disclosed |
| CN-119185524-A | Recombinant protein subunit vaccine for preventing highly pathogenic avian influenza H7N9 and preparation method thereof | 华南农业大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-119044498-A | Claudin-15 protein detection method and related products and application thereof | 苏州和锐生物科技有限公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-4463135-A2 | METHODS OF EX VIVO DOSING AND ADMINISTRATION OF LIPID PARTICLES OR VIRAL VECTORS AND RELATED SYSTEMS AND USES | Sana Biotechnology, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118978591-A | Anti-cryptococcus capsular polysaccharide monoclonal antibody, coding gene thereof, expression and application thereof | 河北康立德生物科技有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118974246-A | Production of rebaudioside | 株式会社三养社 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240294610-A1 | PEPTIDE FOR TREATING AGE-RELATED MACULAR DEGENERATION | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-118581067-A | Method for selecting high M6P recombinant proteins | 阿米库斯治疗学公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118581102-A | Corn aspergillus flavus resistance gene ZmAFR, expression product, excellent haplotype and application thereof in corn breeding | 河南农业大学 | 2024-09-03 | — | — | CN | disclosed |
| CN-118562767-A | Method for selecting high M6P recombinant proteins | 阿米库斯治疗学公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-111801580-B | Method for quantifying a polypeptide | 建新公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240279362-A1 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | SANOFI (FR) | 2024-08-22 | — | — | US | disclosed |
| CN-118496381-A | Chimeric antigen receptor polypeptide, nucleic acid, vector, lentivirus for simultaneously expressing mbIL-15 cytokine and CXCR5 chemokine receptor and application | 天津市第一中心医院 | 2024-08-16 | — | — | CN | disclosed |
| US-20240270803-A1 | PEPTIDE FOR TREATING RETINITIS PIGMENTOSA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-15 | — | — | US | disclosed |
| US-20240271329-A1 | CYCLIC COMPOUND LIBRARY AND CONSTRUCTION METHOD THEREFOR | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2024-08-15 | — | — | US | disclosed |
| US-20240269198-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH FUNGI AND OTHER PATHOGENIC MICROBES | DERMBIONT, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-3967217-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-116970080-B | Anti-human MFAP5 monoclonal antibody and preparation method thereof, polynucleotide molecule, expression vector and host cell | 优睿赛思(武汉)生物科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118489006-A | Glycosyltransferase variants and methods of making steviol glycosides using the same | 株式会社三养社 | 2024-08-13 | — | — | CN | disclosed |
| CN-110234760-B | Peptides for the treatment of age-related macular degeneration | 第一三共株式会社 | 2024-08-06 | — | — | CN | disclosed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240230622-A9 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118103059-A | Self-assembled nanoparticles based on amphiphilic peptides | 巴林萨斯生物疗法北美公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118063573-A | Arginine-specific transcription regulatory factor mutant and application thereof | 中国科学院天津工业生物技术研究所 | 2024-05-24 | — | — | CN | disclosed |
| US-20240165006-A1 | DERMATOLOGICAL COMPOSTIONS AND USE THEREOF | BONE SCI. BIO LTD. (IL) | 2024-05-23 | — | — | US | disclosed |
| EP-4370150-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | Intervet International B.V. (NL) | 2024-05-22 | — | — | EP | disclosed |
| US-20240150742-A1 | GENE FOR EFFICIENTLY EXPRESSING HYALURONIC ACID HYDROLASE AND EXPRESSION METHOD THEREOF | BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
| US-20240133865-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-25 | — | — | US | disclosed |
| US-11965030-B2 | Multispecific binding proteins with mutant fab domains | SANOFI (FR) | 2024-04-23 | — | — | US | disclosed |
| CN-117551170-B | ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof | 中国科学院烟台海岸带研究所 | 2024-04-19 | — | — | CN | disclosed |
| US-20240124602-A1 | ANTI-CD20 ANTIBODY AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240124601-A1 | ANTI-CD20 ANTIBODY AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER | 2024-04-18 | — | — | US | disclosed |
| CN-117844819-A | ZmSht1 gene and application thereof in improving high-temperature-resistant strong light stress of corn | 安徽农业大学 | 2024-04-09 | — | — | CN | disclosed |
| US-11939595-B2 | Nanoscale artificial antigen presenting cells | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-26 | — | — | US | disclosed |
| CN-117757876-A | Double-enzyme catalysis preparation method of 2' -deoxy-2-fluoroadenosine | 上海合润远生物技术有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-109476732-B | Trispecific and/or trivalent binding proteins | 赛诺菲 | 2024-03-22 | — | — | CN | disclosed |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | AMUNIX PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-114656522-B | Antioxidant peptide and preparation method and application thereof | 江苏科技大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-114656522-B | Antioxidant peptide and preparation method and application thereof | 江苏科技大学 | 2024-03-19 | — | — | CN | disclosed |
| US-11932704-B2 | Trispecific and/or trivalent binding proteins | SANOFI (FR) | 2024-03-19 | — | — | US | disclosed |
| CN-117551170-A | ACE (angiotensin converting enzyme) inhibitory peptide as well as preparation method and application thereof | 中国科学院烟台海岸带研究所 | 2024-02-13 | — | — | CN | disclosed |
| EP-4313105-A1 | DERMATOLOGICAL COMPOSITIONS AND USE THEREOF | Bone Sci. Bio Ltd. (IL) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313120-A1 | TREATMENT OF PAIN & INFLAMMATORY DISORDERS | Ipsen Biopharm Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117462693-A | XTEN conjugate compositions and methods of making the same | 阿穆尼克斯运营公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4309665-A1 | CYCLIC COMPOUND LIBRARY AND CONSTRUCTION METHOD THEREFOR | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-20240019417-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018201-A1 | METHODS FOR PURIFICATION OF MULTI-SPECIFIC ANTIBODIES | SANOFI (FR) | 2024-01-18 | — | — | US | disclosed |
| CN-117396218-A | Treatment of pain and inflammatory diseases | 益普生生物制药有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117396217-A | Catalytically inactive clostridial neurotoxins for use in the treatment of pain and inflammatory diseases | 益普生生物制药有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-11866472-B2 | Peptide for treating retinitis pigmentosa | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-01-09 | — | — | US | disclosed |
| EP-4297773-A1 | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS | Ipsen Biopharm Limited (GB) | 2024-01-03 | — | — | EP | disclosed |
| US-20230416392-A1 | ANTI-CD20 ANTIBODY AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023237690-A2 | METHODS FOR PURIFICATION OF MULTI-SPECIFIC ANTIBODIES | SANOFI (FR) | 2023-12-14 | — | — | WO | disclosed |
| US-20230391888-A1 | PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS | SANOFI (FR) | 2023-12-07 | — | — | US | disclosed |
| CN-117083075-A | Dermatological composition and use thereof | 邦赛生物有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069855-A | Trispecific and/or trivalent binding proteins for the prevention or treatment of HIV infection | 赛诺菲 | 2023-11-17 | — | — | CN | disclosed |
| EP-4276105-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd (CN) | 2023-11-15 | — | — | EP | disclosed |
| US-11806365-B2 | Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis | CELGENE CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116041476-B | MALK derived from pig liver to express antibacterial peptide, and preparation method and application thereof | 东北农业大学 | 2023-10-27 | — | — | CN | disclosed |
| EP-3561056-B1 | PEPTIDE FOR TREATING AGE-RELATED MACULAR DEGENERATION | DAIICHI SANKYO CO LTD (JP) | 2023-10-25 | — | — | EP | disclosed |
| EP-4257193-A2 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | Sanofi (FR) | 2023-10-11 | — | — | EP | disclosed |
| US-11779651-B2 | Bivalent, bispecific binding proteins for prevention or treatment of HIV infection | SANOFI (FR) | 2023-10-10 | — | — | US | disclosed |
| WO-2023193015-A1 | CYTOKINE RECEPTOR AGONIST AND VIRAL VECTOR COMBINATION THERAPIES | SANA BIOTECHNOLOGY, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303626-A1 | MACROCYCLIC POLYPEPTIDES | UNIVERSITY OF WASHINGTON | 2023-09-28 | — | — | US | disclosed |
| CN-116789841-A | Trispecific and/or trivalent binding proteins for the prevention or treatment of HIV infection | 赛诺菲 | 2023-09-22 | — | — | CN | disclosed |
| US-11753440-B2 | Methods for the synthesis of arginine-containing peptides | DSM IP ASSETS B.V. (NL) | 2023-09-12 | — | — | US | disclosed |
| US-11754573-B2 | Methods for the quantitation of polypeptides | GENZYME CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116685338-A | Compositions and methods for improving skin health and for treating and preventing diseases, disorders and conditions associated with fungi and other pathogenic microorganisms | 德慕拜昂生物科技公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116675776-A | Trispecific and/or trivalent binding proteins for the prevention or treatment of HIV infection | 赛诺菲 | 2023-09-01 | — | — | CN | disclosed |
| US-11739160-B2 | PseudoFab-based multispecific binding proteins | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| EP-4228665-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH FUNGI AND OTHER PATHOGENIC MICROBES | Dermbiont, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116583605-A | Process for producing L-amino acid | 味之素株式会社 | 2023-08-11 | — | — | CN | disclosed |
| EP-3443006-B1 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | SANOFI SA (FR) | 2023-08-02 | — | — | EP | disclosed |
| CN-116490778-A | Compositions and methods for preventing, inhibiting, disrupting or treating a multi-microbial biofilm | 国家儿童医院研究所 | 2023-07-25 | — | — | CN | disclosed |
| US-20230227778-A1 | COMPOSITIONS AND METHODS OF GENERATING AN IMMUNE RESPONSE | INTIMA BIOSCIENCE, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023133595-A2 | METHODS OF EX VIVO DOSING AND ADMINISTRATION OF LIPID PARTICLES OR VIRAL VECTORS AND RELATED SYSTEMS AND USES | SANA BIOTECHNOLOGY, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023121427-A1 | GLYCOSYLTRANSFERASE VARIANT, AND METHOD OF PREPARING STEVIOL GLYCOSIDES USING SAME | 주식회사 삼양사 | 2023-06-29 | — | — | WO | disclosed |
| CN-110325544-B | Peptide fragment derived from insulin A chain and pharmaceutical composition for preventing or treating diabetes or diabetic wound comprising the same | 舒帕得力克瑞股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116287039-A | Biological method for synthesizing spermidine by cell-free catalysis | 南京工业大学 | 2023-06-23 | — | — | CN | disclosed |
| US-11674948-B2 | Methods and systems for determining autism spectrum disorder risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673961-B2 | Anti-CD20 antibody and uses thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673930-B2 | IL10 agonists and methods of use thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| CN-116096239-A | Combination therapy for the treatment and prevention of biological membranes | 国家儿童医院研究所 | 2023-05-09 | — | — | CN | disclosed |
| CN-111265653-B | Application of atrial natriuretic peptide in preparation of medicines for treating inflammatory bowel disease | 华中科技大学同济医学院附属协和医院 | 2023-05-09 | — | — | CN | disclosed |
| CN-116041476-A | MALK derived from pig liver to express antibacterial peptide, and preparation method and application thereof | 东北农业大学 | 2023-05-02 | — | — | CN | disclosed |
| US-20230130132-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMPHIPHILIC PEPTIDES AND METHODS OF USE THEREOF | BONE SCI. BIO LTD. (IL) | 2023-04-27 | — | — | US | disclosed |
| US-11628221-B2 | Peptide linker and combination for prodrugs activated by prostate-specific antigen | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-04-18 | — | — | US | disclosed |
| CN-113929750-B | Polypeptide with skin barrier repairing function and application thereof | 中国药科大学 | 2023-04-11 | — | — | CN | disclosed |
| CN-109311966-B | Trispecific and/or trivalent binding proteins for use in the prevention or treatment of HIV infection | 赛诺菲 | 2023-03-10 | — | — | CN | disclosed |
| EP-4125993-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMPHIPHILIC PEPTIDES AND METHODS OF USE THEREOF | Bone Sci. Bio Ltd. (IL) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023285489-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | INTERVET INTERNATIONAL B.V. (NL) | 2023-01-19 | — | — | WO | disclosed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | disclosed |
| US-11524979-B2 | Macrocyclic polypeptides | UNIVERSITY OF WASHINGTON (US) | 2022-12-13 | — | — | US | disclosed |
| EP-4090372-A1 | TARGETING PAR1 AND PAR2 TO REGULATE LIPID AND CHOLESTEROL ABUNDANCE | Mayo Foundation for Medical Education and Research (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220331383-A1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD. (IL) | 2022-10-20 | — | — | US | disclosed |
| WO-2022208039-A1 | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS | IPSEN BIOPHARM LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022208091-A1 | TREATMENT OF PAIN & INFLAMMATORY DISORDERS | IPSEN BIOPHARM LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| CN-115142141-A | Cyclic compound library and method for constructing same | 亚飞（上海）生物医药科技有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2022201146-A1 | DERMATOLOGICAL COMPOSITIONS AND USE THEREOF | BONE SCI. BIO LTD. (IL) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022193902-A1 | CYCLIC COMPOUND LIBRARY AND CONSTRUCTION METHOD THEREFOR | 亚飞上海生物医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| CN-113373128-B | Epoxide hydrolase mutant with improved catalytic efficiency and preparation method thereof | 深圳市微滴科技顾问有限公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-4039710-A2 | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 | SANOFI (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114885609-A | pseudo-Fab based multispecific binding proteins | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
| CN-114805489-A | Polypeptide for repairing skin injury or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220235111-A1 | Variant Single-Chain Insulin Analogues | CASE WESTERN RESERVE UNIVERSITY | 2022-07-28 | — | — | US | disclosed |
| US-20220226495-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | SANOFI (FR) | 2022-07-21 | — | — | US | disclosed |
| WO-2022148289-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | 四川好医生攀西药业有限责任公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2022143217-A1 | MEDICAL DEVICE, AND HYDROGEL, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 广州图微科创生物科技有限公司 | 2022-07-07 | — | — | WO | disclosed |
| US-20220211823-A1 | Clostridial Neurotoxins Comprising an Exogenous Activation Loop | IPSEN BIOPHARM LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| US-20220195529-A1 | ISOFORMS OF GATA6 AND NKX2-1 AS MARKERS FOR DIAGNOSIS AND THERAPY OF CANCER AND AS TARGETS FOR ANTI-CANCER THERAPY | MAX PLANCK GESELLSCHAFT (DE) | 2022-06-23 | — | — | US | disclosed |
| US-20220185891-A1 | METHODS OF ANTI-TUMOR THERAPY | VASCULAR BIOGENICS LTD. (IL) | 2022-06-16 | — | — | US | disclosed |
| EP-4010377-A1 | CELL-SURFACE RECEPTORS RESPONSIVE TO LOSS OF HETEROZYGOSITY | A2 Biotherapeutics, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20220154212-A1 | METHODS OF ANTI-TUMOR THERAPY | VASCULAR BIOGENICS LTD. (IL) | 2022-05-19 | — | — | US | disclosed |
| US-11312974-B2 | Gene for increasing plant biomass and use therefor | KANEKA CORPORATION (JP) | 2022-04-26 | — | — | US | disclosed |
| US-11311583-B2 | Treatment methods using adenovirus | Vascular Biogenetics Ltd. (IL) | 2022-04-26 | — | — | US | disclosed |
| US-20220119553-A1 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | SANOFI (FR) | 2022-04-21 | — | — | US | disclosed |
| WO-2022081762-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH FUNGI AND OTHER PATHOGENIC MICROBES | DERMBIONT, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-114230668-A | anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123 | 赛诺菲 | 2022-03-25 | — | — | CN | disclosed |
| CN-114230667-A | anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123 | 赛诺菲 | 2022-03-25 | — | — | CN | disclosed |
| US-20220088209-A1 | PEPTIDE LINKER AND COMBINATION FOR PRODRUGS ACTIVATED BY PROSTATE-SPECIFIC ANTIGEN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-03-24 | — | — | US | disclosed |
| EP-3967217-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220048988-A1 | CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME | CHILDREN'S NATIONAL MEDICAL CENTER | 2022-02-17 | — | — | US | disclosed |
| EP-3954991-A2 | METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK | Laboratory Corporation of America Holdings (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952903-A1 | METHODS OF ANTI-TUMOR THERAPY | Vascular Biogenics Ltd. (IL) | 2022-02-16 | — | — | EP | disclosed |
| US-7846902-B2 | Dipeptide-comprising composition for oral administration | KYOWA HAKKO BIO CO., LTD. (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080305151-A1 | Dipeptide-Comprising Composition for Oral Administration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| EP-1941896-A1 | DIPEPTIDE-CONTAINING COMPOSITION FOR ORAL ADMINISTRATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-1992010562-A1 | GANODERMA LUCIDIUM IY009 WHICH PRODUCES PROTEOGLYCAN (G009) HAVING EFFECT OF ENHANCING ANTITUMOR IMMUNITY | IL-YANG PHARMACEUTICAL CO., LTD. (KR) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010562-A1 | GANODERMA LUCIDIUM IY009 WHICH PRODUCES PROTEOGLYCAN (G009) HAVING EFFECT OF ENHANCING ANTITUMOR IMMUNITY | IL-YANG PHARMACEUTICAL CO., LTD. (KR) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628221-B2 | Peptide linker and combination for prodrugs activated by prostate-specific antigen | KLK3, DNPEP, FOLH1 | ALDH1A1 2579/4885MEN1 1123/4885LMNA 3367/4885 |
| US-20220088209-A1 | PEPTIDE LINKER AND COMBINATION FOR PRODRUGS ACTIVATED BY PROSTATE-SPECIFIC ANTIGEN | KLK3, DNPEP, FOLH1 | ALDH1A1 2579/4885MEN1 1123/4885LMNA 3367/4885 |
| US-12537071-B1 | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins | ANTXR2, BCOR, ZFX | ALDH1A1 4877/4885MEN1 1519/4885LMNA 3115/4885 |
| US-20250154549-A1 | GLYCOSYLTRANSFERASE VARIANT, AND METHOD OF PREPARING STEVIOL GLYCOSIDES USING SAME | UGGT1, UGCG, STT3A | ALDH1A1 1161/4885MEN1 2322/4885LMNA 4731/4885 |
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | PDXK, VIP, F13B | ALDH1A1 4454/4885MEN1 3186/4885LMNA 365/4885 |
| US-12570755-B2 | Anti-CD20 antibody and uses thereof | CD209, BCL9, BCR | ALDH1A1 3924/4885MEN1 2343/4885LMNA 4135/4885 |
| US-20240091315-A1 | XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME | XPA, TXLNA, NGLY1 | ALDH1A1 3685/4885MEN1 455/4885LMNA 2236/4885 |
| US-20250312475-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | CD4, HAVCR2, TIMCC | ALDH1A1 4813/4885MEN1 4620/4885LMNA 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.